Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
As part of its global expansion plans, Dabur Pharma has acquired the sales and distribution network of Thailand-based Bioscience for an undisclosed sum.
Dabur Pharma launched its new nano technology-based chemotherapy agent Nanoxel in the country on Thursday.
Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.
Sources close to the development said this could happen at a meeting of the company's board of directors on Thursday.
In a move to focus on its core FMCG strength, the Burman family, promoters of Dabur India, last week announced their exit from the pharma business.
To shed its mass market tag, Dabur to focus on health juices rather than fruit drinks. While the pharma sector in India may be looking up, for the Dabur Group, the move is in line with its desire to maintain a strong foothold in the FMCG sector that is poised to grow by 16 per cent this financial year compared to the 12 per cent growth rate in pharma.
Dabur Pharma has sold its entire non-oncology business to Alembic for approximately Rs 167 crore
Dabur India on Wednesday said it was in talks with three firms to acquire their brands, while also acquiring a brand from its sister concern Dabur Pharma and introducing more products this fiscal.
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances